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ABSTRACT
Breast cancer is the leading cause of death among women and is highly heterogeneous in
nature. One very aggressive subtype of this disease is Triple Negative Breast Cancer. Triple
Negative Breast Cancer (TNBC), is a very aggressive disease characterized by the lack of
expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth
factor receptor-2 (HER-2). TNBC patients account for approximately 15% of total breast cancer
patients. This breast cancer subtype is characterized by high mortality rate, and is typically
associated with poor prognosis. Current clinical methods have proven to have low success rates
against TNBC, it is proposed that prevention by dietary approach with naturally occurring
compounds in foods will be more effective. The objective of this research was to study the
inhibitory activity of black seed oil and potassium chloride against the biomarkers of triple
negative breast cancer. Hormone-independent MDA-MB-231 breast cancer cells were incubated
with black seed oil, potassium chloride, or the combination of black seed oil with potassium
chloride and incubated at 37 ºC and 5% CO2 in a humidified incubator for 24, 48, or 72 h. Cell
viability was measured by MTS assay. The effect of black seed oil on angiogenesis was
determined using in vitro angiogenesis tube formation assay. Cancer cell cycle was analyzed by
flow cytometry. The expression levels of biomarkers of TNBC cells were evaluated by Western
blots. This study showed that black seed oil and potassium chloride proved efficient in downregulating TNBC associated biomarkers including ALDH1, CD44, ESA, PI3K/Akt, Erk, COX-2,
NFκB, Hsp90, p53, p21, Bax, and Bcl-2. The results indicate that black seed oil or KCl or their
combination can attenuate the biomarkers of triple negative breast cancer MDA-MB-231,
suggesting a potential preventive role against the disease.
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CHAPTER 1:
INTRODUCTION
Breast cancer is the second most common cancer in the world and most common cancer
among women (Key and others 2003). It is a leading cause of death in women and this disease is
highly heterogeneous in nature. Triple Negative Breast Cancer (TNBC), which is a subtype of
inflammatory breast cancer, is a very aggressive disease with poor prognosis. The malfunction in
the DNA repair process leading to increased apoptosis and defective cell cycle, contributes to the
poor prognosis of this disease.
The disease is characterized by a lack of targeted therapies, and is highly chemosensitive. There are current challenges faced by chemotherapy treatment for this disease, such as
a lack of established targets, resulting in its low success rate. With the still unmet responses to
the challenges of this disease, there arises strong need for more efficacious treatment options.
The poor prognosis and low success rates of treatments associated with triple negative breast
cancer implies that prevention by dietary approach would be better, thus the use of non-toxic
naturally occurring bioactive compounds may be more effective and may be the best approach in
targeting this disease.
Sustained angiogenesis is one of the known hallmarks of cancer. Angiogenesis is the
formation of new blood vessels from pre-existing ones. It is a process that occurs normally in life
but also plays a role in various disease conditions when there is an imbalance in the regular
process of angiogenic stimulation and inhibition. The process of angiogenesis advances tumor
growth and metastasis by the disruption of basement membrane of endothelial cells, cell
proliferation, migration, and finally formation of new three dimensional tubular structures.
Targeting angiogenic factors is one of the major approaches to cancer treatment and prevention.
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It is well established that there are various mechanisms which may lead to an increased
risk of breast cancer due to its inherent heterogeneity. One major risk factor is proved by the
evidence that nutritional factors can affect breast cancer risk either positively or negatively
through hormonal mechanisms; For example, saturated fat can pose negative risk (Key and
others 2003). It is proposed that dietary bioactive compounds will carry out inhibitory activities
against the growth and metastasis of cancerous cells without affecting normal breast cells. This
will result in better patient treatment outcomes including the prevention of relapse, moreover
improving prognosis, and ultimately increasing overall survival rates (Altenburg and others
2011; George and others 2011). Prevention has been recognized by world top oncologists as the
best cure for cancer, food can prevent cancer from progressing and causing death.
Dietary bioactive compounds that promote cancer inhibition have been identified and
studied. Some of which include curcumin, epigallocatechin, resveratrol, diosgenin,
thymoquinone, etc. The focus for this study was black seed oil, extracted from black seed also
known as black cumin seed, or Nigella Sativa. The main bioactive component in black seed oil is
thymoquinone which has been found to possess inhibitory properties against cancer cell
proliferation, and to induce apoptosis in various human cancers (Gali-Muhtasib and others 2006).
The main objective of this study was to investigate the interaction of black seed oil
(BSO) or potassium chloride (KCl) or a combination of the oil with potassium chloride with the
biomarkers of triple negative breast cancer. The steps taken to test this objective include:
1)

Investigation of the cancer cell viability after treatments with BSO, KCl and the
combination of both treatments.

2)

Analyses on the effects of the treatments on cell cycle, angiogenesis, and signal
transduction pathways associated with TNBC
2

CHAPTER 2:
LITERATURE REVIEW
2.1. Breast Cancer
Breast cancer is a complex disease which is heterogeneous in nature (Bosch and others
2010; Oakman and others 2010), with diverse outcomes and responses to treatment (Oakman and
others 2010). It is the most common diagnosed malignancy in women (Giovannini and others
2010). It is the most common cancer in women and the leading cause of death (Irminger-Finger
2010; Irvin Jr and Carey 2008). The statistics in 2007 show that 1,300,000 women were
diagnosed with breast cancer and 465,000 died from breast cancer worldwide. In the United
States, 182,480 new diagnoses and 40,170 deaths were estimated in 2009 (Sun and others 2010).
The American Cancer Society (ACS) estimated 207,090 new cases of invasive breast cancer
diagnosis in women and 39,840 deaths for 2010. The trends show an increase in breast cancer
diagnoses.
Various risk factors influence the development of breast cancer such as age, gender, race,
dietary and life-style habits, physical activity, and breast cancer susceptibility gene mutation
carriers (Tot 2011). Breast cancer cells have the ability to metastasize and spread to other sites in
the body. One major way this occurs is through the lymphatic system. Most of the lymph vessels
lead to axillary lymph nodes located under the arms (see Figure 2.1). The cells can enter the
lymphatic vessels and begin to grow in lymph nodes and cause the lymph nodes to swell. There
is higher likelihood that cancerous cells will be found in the blood stream and other parts of the
body once the cancerous cells get into the axillary lymph nodes and if there are more lymph
nodes with cancer cells (Cancer 2010). The many different types of breast cancer mainly
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constitute of about 80% invasive ductal carcinomas, and 10-15% invasive lobular carcinomas
while the rest (5-10%) are the additional rare types (Hwang-Verslues and others 2009).

Figure 2.1: The Lymphatic system
Breast cancer has been defined and classified using a number of clinical and pathologic
features (such as age, tumor size, hormonal receptor status, etc) for outcome predictions and
response to treatment (Bosch and others 2010; Irvin Jr and Carey 2008). A validated classification
based on gene-expression assays considered four breast cancer subtypes (Table 2.1.) The classes
include: luminal, human epidermal growth factor receptor (HER2 or ERBB2) positive, normal
breast, and basal like (Bosch and others 2010; Hwang-Verslues and others 2009).
Table 2.1: Breast cancer classification based on gene-expression
Breast Cancer Subtype
Luminal
ERBB2 +
Normal breast subtype
Basal-like

Characteristics
High expression of many genes expressed by breast luminal cells
cytokeratins (8/18)and estrogen receptors
Does not overexpress ERBB2.
Overexpression of ERBB2 oncogene
Low levels of estrogen receptor (ER) expressions and all genes
associated with it.
Expression of genes distinctive of basal epithelial and adipose cells
Low expression of luminal cells gene clutter
High expression of cytokeratin 5/6 and 17, fatty acid binding protein7
Failure to express ER and most genes co-expressed with it
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Breast cancer is also classified based on clinical manifestations such as inflammatory and
non-inflammatory breast cancer. The highly aggressive form, inflammatory breast cancer, was
the main focus for this study and will be discussed in more detail.
2.2. Inflammatory Breast Cancer
A discrete clinical and pathologic entity with rapid disease progression and poor
prognosis describe a form of breast cancer among the most metastatic variants of breastcancer
known as inflammatory breast cancer (IBC) (Cariati and others 2005; Lopez and Porter 1996).
Though IBC represents less than 10% of all breast cancers, it is the most lethal form of the
disease (Ben Hamida and others 2008). The lethality of IBC is ascribed to its high invasive
nature (Hoffmeyer and others 2005).
The American Joint Committee on Cancer (AJCC) defines IBC as “a clinicopathologic
entity characterized clinically by diffuse edema and erythema of the breast, over the majority of
the breast, and often without an underlying mass. The clinical appearance is due to pathologic
plugging of the dermal lymphatics of the breast, but pathologic involvement of the dermal
lymphatics alone does not confirm the diagnostics” (Anderson and others 2005) .
The main features that distinguish inflammatory breast cancer from other forms of breast
cancer are its distinct phenotype, which includes rapidly progressive breast inflammation, and a
high tendency for metastasis to occur (Lerebours and others 2008; Zell and others 2009). This
suggests a high propensity for tumor cells to migrate (Ben Hamida and others 2008). The
survival rate is significantly different from the non-inflammatory forms of breast cancer: a 3-yr
survival rate is about 40% compared to non-inflammatory breast cancers with 85% (Lerebours
and others 2008).
5

Inflammatory-like symptoms such as redness, warmth, and edema prevent proper
diagnosis of the disease. A change in breast skin texture with similarities to that of an orange
peel is a characteristic of IBC (Hoffmeyer and others 2005). This does not occur as a result of
true physiologic inflammatory response (Anderson and others 2005). It is due, rather to extensive
invasion of the dermal lymphatics by IBC tumor cell emboli (Anderson and others 2005;
Hoffmeyer and others 2005). Thus, by the time proper diagnosis is made, the cancer would have
aggressively filtered through surrounding tissues and the lymphatic system, leading to poor
prognosis (Hoffmeyer and others 2005).
The descriptions of several molecular alterations in IBC include frequent hormone
receptor negativity, TP53 mutations and HER2 amplifications (Lerebours and others 2008). Most
studies have focused on the role of estrogen and progesterone receptors for investigations on the
molecular basis of IBC. The majority of IBCs are estrogen receptor negative (Cariati and others
2005).
2.3.Triple Negative Breast Cancer
A lack in the expression of estrogen receptors (ER), progesterone receptors (PR) and
human epidermal growth factor receptor-2 (HER-2) results in an aggressive type of cancer
referred to as Triple Negative Breast Cancer (TNBC) (Carotenuto and others 2010; Chen and
Russo 2009; Liedtke and others 2008; Oakman and others 2010; Podo and others 2010). TNBC
accounts for approximately 25% of the total breast cancer population, and mostly occurs in
young women originating from African, African-American, and Latino ethnic groups
(Carotenuto and others 2010; Chen and Russo 2009). This type of cancer is also dominant among
obese women (Chen and Russo 2009). According to Hortobagyi (2008), forty percent of
inflammatory breast cancers are likely to be triple negative. TNBC is typically associated with
6

poor prognosis due to aggressive tumor phenotype(s), only partial response to chemotherapy, and
present lack of clinically established targeted therapies (Podo and others 2010). As seen in Table
2.2, TNBC subtype is highly heterogeneous in itself and is not one disease as it also has various
subtypes (Adamo and Anders 2011; Oakman and others 2010).
Table 2.2: Various Subtypes of TNBC

Poor Prognosis
Invasive ductal carcinoma NOS
Invasive lobular carcinoma
Metaplastic carcinoma
Myoepithelial carcinoma
High grade neuroendocrine (oat-cell) carcinoma

Good Prognosis
Apocrine carcinoma
Medullary carcinoma
Secretory breast carcinoma
Adenoid cystic carcinoma
Metaplastic carcinoma (adenosquamous and fibromatosis-like)

The absence of expression of estrogen receptor, progesterone receptor, and HER2 (also
referred to as ERBB2), and proving the worst outcomes with no therapeutic targets, makes the
basal-like subtype of breast cancer one of relevance (Bosch and others 2010). Basal like breast
cancer has characteristic features that include the triple negative phenotype however it has been
stated that Triple Negative and Basal-like are not equivalent terms (Bosch and others 2010;
Carotenuto and others 2010; Irvin Jr and Carey 2008; Oakman and others 2010). The term basallike breast cancer was coined to describe the tumors that overexpressed genes characterizing
breast basal epithelial cells while triple negative is based on clinical observations describing
7

breast cancers that do not stain for ER, PR, and HER2 in immunohistochemistry studies (Bosch
and others 2010).
Research shows that patients with the basal-like subtype of breast cancer have poorer
prognosis than patients with the Luminal subtype (Lorico and Rappa 2011). ER negative basal
subtypes are associated shorter relapse and overall survival times with patients, than luminal ER
positive subtypes (Rosen and others 2010). A study done with different breast cancer subtypesluminal, ERBB2+, and basal-like showed shorter survival and overall disease-free survival with
ERBB2+ and basal-like patients while it was longer for Luminal A subtype patients (Bosch and
others 2010). The differences in survival could be explained by the overexpression of ERBB2
(an oncoprotein) and presence of TP53 mutations which are associated with poor survival, as
TP53 mutation levels were higher in ERBB2+ and basal-like types but not in Luminal A
subtype. This shows that TP53 mutation is related to the lack of expression of ER and poor
prognosis as seen in TNBC (Bosch and others 2010).
TNBC patients are also associated with high or early relapse (Carotenuto and others
2010; Chen and Russo 2009). TN tumors have worse relapse-free and overall survival for
patients (Bosch and others 2010; Stratford and others 2010). Women with TNBC are twice as
likely as other women to develop distant metastases, causing a shorter survival in TNBC patients
as this disease condition has high malignancy, poor differentiation and is very aggressive (Chen
and Russo 2009). The lack of expression of ER, PR, and HER-2 makes treatment of TNBC
difficult. Patients are mostly only treated with standard chemotherapy due to the lack of
expression of ER, PR, and HER-2, preventing treatment with more specific targeted therapy
(Chen and Russo 2009). ER and PR were the first clinically used predictive prognostic markers
for breast cancer arising from the exposition of hormonal regulation while HER-2 gene
8

amplification and protein over-expression have been the first cytogenic predictor for breast
cancer treatment (Podo and others 2010; Rosen and others 2010).
Estrogens are essential for normal growth and differentiation of human breast epithelial
cells. However, exposure to excess estrogens for a prolonged time is an important etiological
factor for the development of breast cancer. The presence of ER in breast tumors is used to
predict response to endocrine therapies and disease prognosis. Progesterone and progesterone
receptors are essential for estrogen promotion of breast cancer (Chen and Russo 2009).
Human epidermal growth factor receptor (HER) is essential for normal breast growth and
development and plays a key role in tumor development (Rosen and others 2010). Furthermore,
gene-amplification and/ or over expression of HER-2 are key hallmarks in ER positive breast
cancer patients (Alvarez and Price 2010; Chen and Russo 2009). It has been shown that HER-2
over expression caused metastatic outgrowth of breast cancer cells in the brain (Chen and Russo
2009). The HER family mediates a wide range of signals controlling various cellular process
such as cell proliferation, angiogenesis, and apoptosis; however, HER2 is the preferred signaling
partner for other members of the HER family (Rosen and others 2010). Thus, it serves as a great
treatment target. The evaluation of HER2 overexpression guides in treatment selection and
efficiency of treatment (Alvarez and Price 2010; Rosen and others 2010). Therefore, the absence
of these essential breast cancer markers makes this disease very difficult to treat.
Several features with breast cancer susceptibility gene (BRCA) outcome-associated
breast cancer also occur with TNBC patients. For example, approximately 20% of breast cancer
patients with mutations in BRCA-1 and BRCA-2 have deficiency in DNA repair because normal
BRCA1 and BRCA2 have an important role in DNA repair (Bosch and others 2010; Chen and
Russo 2009; Podo and others 2010). BRCA1 and BRCA2 gene mutations cause the disruption of
9

breast cell homeostasis which results in breast cancer. BRCA dysfunction can be an important
mechanism in TNBC development (Bosch and others 2010). BRCA1 mutation is not only a
prognostic marker, but also a predictive marker for chemotherapy response (Oakman and others
2010).
BRCA1 and BRCA2 play a role in cell-cycle control. The cell cycle is a series of
coordinated events describing DNA replication and cell division (Collins and others 1997). The
life cycle of the cells is divided in four phases based on DNA content and mitotic activity (Figure
2.2). The cells divide in the M phase (mitosis), proceed on to the G1 phase with constant DNA
content, and then into the S phase where DNA is duplicated. They enter the G2 phase from the S
phase remaining at constant DNA content before going back into the M phase, continuing the
cycle (McGuire and Dressler 1985).

Figure 2.2: The cell cycle process
BRCA1 and BRCA2 regulate tumor suppressor protein p53 activity which functions in
DNA repair. When DNA repair is not possible, cells go into apoptosis, which is the process of
programmed cell death and it is regulated by genetically directed pathways. Apoptosis plays a
10

role in the formation of tumors and makes cells resistant to treatment. The mechanism of
apoptosis is avoided by cancer cells in order for them to thrive (Podo and others 2010; Rosen and
others 2010; Siddiqa and Marciniak 2008). In other words, TNBC patients with problems in
DNA repair make the mutation carriers more sensitive to DNA- damaging agents, leading to
shorter survival and altered expression of a number of proteins, oncogenes, and abnormal
signaling pathways in TNBC patients (Chen and Russo 2009).
Though there is still a poorly understood association of TNBC with BRCA1 mutations
(Podo and others 2010), there is definitely a significant overlap between TNBC, basal-like
phenotype, and BRCA-1 mutated tumors (Oakman and others 2010). The heterogeneous
characteristic of TNBC includes both basal and non-basal-like tumors, and triple negativity is
sometimes used to identify basal-like tumors (Podo and others 2010). Only 71-91% of TNBC
have basal-like phenotype, 77% of basal-like cancers are TNBC, while more than 80% of
BRCA-1 mutations careers are triple negative (Chen and Russo 2009; Oakman and others 2010).
In other words, not all BRCA-1 related breast cancers are TNBC or basal-like cancers (Bosch
and others 2010).
The pathogenesis of TNBC is still not known to a high extent. This is a major challenge
in developing therapies effective for treating this type of cancer (Chen and Russo 2009). The
buildup of defects at the levels of gene amplification, methylation, mutations and other cellular
regulation mechanisms is the underlying cause for disease heterogeneity and differential
response to treatment. Understanding the relations between potential TNBC markers may help to
realize the heterogeneity of these tumors and improve the response prediction to both single
agents and combination treatments (Podo and others 2010). It may not be likely that a single
biomarker will provide reliable prognostic information for a patient. Multiparameter
11

technologies such as proteomic or gene expression analyses give high expectations and will be
more productive than analyzing a single gene or protein (Alvarez and Price 2010). The patient
and tumor characteristics and treatment outcomes of TNBC are summarized in Table 2.3.
Table 2.3: Summary of clinical features of triple-negative tumors.
Patient characteristics

Younger age at diagnosis
Predominantly African origin
BRCA1 mutation carrier

Tumor characteristics

Ductal invasive carcinoma
Rare histology (medullary, metaplastic)
Negativity for ER, PR and HER-2
Elevated mitotic count
Tumor necrosis
Highly invasive
Larger tumor size
Axillary node involvement

Treatment/prognosis

Chemosensitive
No clinically established specific targets
Poorer prognosis
Aggressive relapse (trend of relapse
within first 3 years)

2.4. Angiogenesis and TNBC
Angiogenesis is the formation of blood vessels from a pre-existing one and is an
important process of tumoregenesis. (Auerbach and others 2003; Chen and Russo 2009). This
process is an integral part of both normal developmental processes and numerous pathologies
including inflammation and tumor growth (Auerbach and others 2003). It is essential for organ
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growth and repair; however an imbalance in the process results in numerous malignant,
inflammatory, infectious and immune disorders (Carmeliet 2005).
The principal cells involved are endothelial cells which line all blood vessels and
constitute virtually the entirety of capillaries. Figure 2.3 shows a summary of the angiogenesis
process. For the formation of new blood vessels, endothelial cells must first break through the
basement membrane, escaping from their stable location. Then the endothelial cells migrate
toward an angiogenic stimulus (Auerbach and others 2003). Behind this migrating front,
endothelial cells proliferate to form the necessary number of cells for making a new vessel, and
then the new outgrowth of endothelial cells needs to reorganize into a patent three dimensional
tube structure (Auerbach and others 2003).

Angiogenic
factor
production

release of
angiogenic
factors

endothelial cell
receptor
binding

cell
prolieferation

vascular
stabilization

tube and loop
formation

endothelial cell
matrix
remodelling

directional
migration

Figure 2.3: Summary of angiogenic process
Angiogenesis remains inactive during adulthood except in the cycling ovary and in the
placenta during pregnancy. However, endothelial cells retain their ability to divide quickly in
response to physicochemical stimulus such as hypoxia in blood vessels and in lymph vessels, and
inflammation (Carmeliet 2005). In most disorders, this stimulus becomes excessive, resulting in
an angiogenic switch due to an imbalance between stimulators and inhibitors. This is what
occurs in most inflammatory disorders leading to additional processes responsible for diseases
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such as obesity, asthma, diabetes, cirrhosis, multiple sclerosis, etc (Carmeliet 2005), whereas the
stimulators are undersupplied in other situations causing the dysfunction of endothelial cells,
vessel malformation or regression, or preventing healing and regeneration. Angiogenesis has
been linked with over 70 disorders and the list is still growing (Carmeliet 2005).
Angiogenesis does not initiate malignancy, but promotes tumor progression and
metastasis as the tumor progresses from micrometastases to lethal macrometastases which is
what mostly leads to death in cancer patients (Carmeliet 2005; Rosen and others 2010; Siddiqa
and Marciniak 2008). The angiogenesis process is a fundamental mechanism in tumor growth
and development into detectable masses (Bosch and others 2010; Rosen and others 2010).
Angiogenesis plays a role in the aggressive IBC, TNBC. High VEGF, which is the key factor in
angiogenesis, is correlated with poor prognosis and response (which are the main characteristics
of TNBC). VEGF levels are a prognostic factor for relapse-free and overall survival in patients;
in addition, PDGFR-α has been connected with aggressiveness (Carvalho and others 2005; Relf
and others 1997). Each step in neovascularization or angiogenesis, including the disruption of
the basement membrane, cell proliferation, cell migration, and tube formation, can be a target for
intervention (Auerbach and others 2003). Targeting just one step such as cell proliferation does
not suffice in the formation of tumor mass (Rosen and others 2010).
2.5. TNBC Associated Biomarkers
Biomarkers are useful in the quantification of the course of malignancy and therapy
response as well as in early identification of cancer patients and in therapy decision (Podo and
others 2010). According to the U.S. Food and Drug Administration (FDA), a biomarker can be
defined as “exploratory”, “probably valid” and “known valid”. A valid biomarker is “measured
in an analytic test system with well-established performance characteristics, and for which there
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is an established scientific framework or body of evidence that elucidates the physiologic,
toxicological, pharmacological, or clinical significance of the test results” (Alvarez and Price
2010). The success of biomarkers depends on: (1) our ability to reveal critical cancer related
molecular events and the mechanisms of action of targeted therapy, and (2) the efficiency of the
relationship of specific biomarker to another and to a certain disease condition (Podo and others
2010).
A number of molecular changes in IBC/ TNBC which contribute to the inherently high
metastasis of IBC have been described (Charafe-Jauffret and others 2010). Some markers which
have been demonstrated to be useful in IBC/ TNBC are p53 and Hsp90. These biomarkers are
useful for the prognostic evaluations, and for therapeutic response predictions which provide
guidance for patient management (Podo and others 2010).
2.5.1. Breast Cancer Stem Cell Biomarkers
There have been no markers demonstrated to predict systemic metastasis development in
IBC, however, there is increasing evidence that human breast cancers are driven by cancer stem
cells (CSC) which initiate tumors with self renewal properties. CSCs have recently been
validated by different studies to be a small cell population resistant to current anticancer
therapies, antimitotic agents, and radiation. CSCs have the ability to sustain tumor formation and
growth, giving rise to multi-lineage differentiated cells which form the tumor (Charafe-Jauffret
and others 2010; Lorico and Rappa 2011). They are referred to as tumor-initiating cells which
are resistant to therapy, and have been said to be probably responsible for the early recurrence in
TNBC (Stratford and others 2010).
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There are various breast cancer stem cell biomarkers. The different breast cancer cell
lines and primary tumors show differences in expression of these CSC. The main cancer stem
cells associated with TNBC include CD44, epithelial specific antigen (ESA), and aldehyde
dehydrogenase (ALDH1) (Hwang-Verslues and others 2009).
2.5.2. TNBC Signal Transduction Biomarkers
Various processes occur either simultaneously or sequentially in tumor cells, producing
signals. Signals from the environment can also lead to conflicting stimuli. Therefore organization
of the processes requires firm coordination of the process events. For example, proteins like p53,
control the expression of a large numbers of genes (Podo and others 2010). Table 2.4 shows
some biomarkers associated with TNBC tumor and patient characteristics and their biological
effects as related to the disease.
Table 2.4:

TNBC associated biomarkers

Biomarker

Biological Effects

Akt

Cell proliferation
Cell growth

ERK /MAPK

Cell proliferation
Increased migration and invasion

Hsp90

Regulator of HER family
Apoptosis

P53

Apoptosis/ Defective DNA repair
Cell proliferation/ Cell cycle

Bax/ Bcl-2

Apoptosis

VEGF

Angiogenesis

NFκB

Inflammation

16

TNBC is known to have implications on cell signaling pathways, tumor metabolism,
evasion of cell-cycle control, invasion, and metastasis. TNBC also affects a high number of
genes associated with cell proliferation, frequent p53 mutations, reduced DNA repair capability,
and increased angiogenesis (Oakman and others 2010).
2.6. Treatment Options and Responses
The main currently used treatment for breast cancer is chemotherapy. The cytotoxic
effects of chemotherapeutic compounds occur by interference with DNA or RNA functions
(Kitano 2004). It has been demonstrated that TNBC is a chemo-sensitive disease which escapes
control by current standard treatments and with a lack of clinically established targets (Bosch and
others 2010; Podo and others 2010). Some biological and chemotherapeutic agents are currently
being tested either singly or in combination with other agents to increase treatment effectiveness.
These agents directly target biomarkers associated with this highly metastatic breast cancer.
Some treatment agents in trial are seen in Table 2.5. Though these therapies are being used, there
are limitations and challenges being faced in using them.
Table 2.5: Possible Agents for TNBC Targeted Therapies
Biomarker/ Signal

Proposed therapeutic agents

pathway
HER1 (EGFR)

Cetuximab; Erlotinib; Gefitinib

P53

Not available

VEGF/VEGFR

Bevacizumab; Sunitinib; Sorafenib

AKT

Perifosine

ERK/ MAPK

ERK kinase inhibitors

Hsp90

Tanespimycin

17

One major challenge in the development of treatment for this disease is the heterogeneity
and complexity of this disease. Most cancer drugs aim at a limited number of targets, however
there are numerous metastatic channels or signal pathways associated with the hallmarks of
cancer which are evading metastasis, self-sufficiency in growth signals, insensitivity to antigrowth signals, limitless replicative potential, tissue invasion and metastasis, and sustained
angiogenesis. A lot of time, money, plus difficulty are involved in the search for targets that are
valid and crucial to the disease (Siddiqa and Marciniak 2008; Tian and others 2010).
More challenges in TNBC treatment include drug resistance, low survival rate
improvements, restrictions on therapies to a subset of patient populations (Rosen and others
2010) and low treatment success. The safety of anti-angiogenic treatment is a topic of emerging
importance (Carmeliet 2005). It is a challenge to find the perfect targeted therapy that is specific
for tumor cells without affecting the normal healthy tissues (Irminger-Finger 2010). One of the
challenges is that chemotherapy or radiation can stimulate tumor initiating cells which could be a
reason for early recurrence in TNBC. As a result of these challenges currently being faced with
the treatment of this aggressive disease, new therapeutic agents are therefore being sought for
TNBC (Stratford and others 2010).
2.7. Functional Foods and Breast Cancer
The present lack of efficacious clinically established targeted therapies demands a need
for better prevention of IBC and TNBC. The currently used chemo-therapeutic agents have
yielded low success rates with awful side-effects in breast cancer patients, leading to numerous
studies on dietary components that will potentially be used in cancer prevention and treatment.
Natural dietary compounds from foods will be less toxic to the human body than chemotherapy
drugs (Lipski 2005). Lifelong dietary habits have a large influence on cancer development thus
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dietary changes may prevent breast cancer development (Hanf and Gonder 2005; Tsubara et al.
2005; Kotsopoulos and Narod 2005).
Some of the various dietary components that have been and/ or are being studied for their
anti-cancer activities are mentioned below. Resveratrol has been shown to have the qualities of
natural chemo preventive agents including N-acetylcysteine, melatonin, reduced lipoic acid, and
phytoestrogens (Chen and Russo 2009). Curcumin from turmeric has been shown to provide
anti-inflammatory effects on biomarkers of IBC such as NF-κB and COX-2 (Jurenka 2009).
Foods with polyphenolic compounds such as some mango varieties and cranberries have been
studied for anti-carcinogenic effects on inflammatory breast cancer cells (Neto 2007; Noratto and
others 2010). It has also been demonstrated that fenugreek has shown anti-cancer activities in the
down-regulation of p53 (Shabbeer and others 2009). Oils from various food sources are also
receiving focus in cancer prevention studies. For example, fish oil has been studied for its
benefits in inhibiting tumor growth and progression (Mandal and others 2010).
2.8. Black Seed
One of the most expansively studied plants, as a result of the growing interest in naturally
occurring compounds with anticancer potential, is Nigella Sativa known as Black Seed or Black
Cumin Seed (Gali-Muhtasib and others 2006; Ramadan 2007). It is a dicotyledon grown in
countries bordering the Mediterranean Sea, Pakistan, and India. The seeds have been used for
thousands of years in a variety of foods such as bread, pastries, yogurt, pickles, soups, sauces,
salad dressings, etc. It is also used externally on the skin or in cosmetics (Goreja 2003;
Hajhashemi and others 2004).
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It has been used for a very long time as a spice and food component, for its medicinal
properties to promote health and prevent diseases, and to aid digestion (Ramadan 2007; Salem
2005; Tauseef Sultan and others 2009). Black seed provides a good source of essential nutrients
with a diverse chemical composition comprising essential fatty acids, amino acids,
carbohydrates, fiber, and minerals such as calcium, iron, etc (Gali-Muhtasib and others 2006;
Tauseef Sultan and others 2009).

Figure 2.4: Black seed plant, black seed, black seed oil
Black seed oil is the spicy yellowish oil with an aromatic flavor and fresh flavored odor
extracted from black cumin seed (Hajhashemi and others 2004; Ramadan 2007). Thymoquinone
(TQ) is the major anticancer bioactive compound in the oil extracted from black seed (Figure
2.5) (Effenberger and others 2010; Gali-Muhtasib and others 2006; Hajhashemi and others 2004;
Ramadan 2007; Velho-Pereira and others 2011).

Figure 2.5: Chemical structure of Thymoquinone
20

It has been shown both in vivo and in vitro that thymoquinone inhibits the proliferation of
various human cancers. Combining TQ with anti-cancer drugs has improved the results of
chemotherapy and reduced their damaging effects to normal cells. Animal models have been
used in numerous studies to demonstrate the promising effects of black seed oil anti-cancer
activities (Gali-Muhtasib and others 2006). Though thymoquinone is the major bioactive
compound of this oil, it has been shown that various compounds in the oil such as thymoquinone,
terpineol, and carvacrol, work synergistically. Thus the importance of using the whole oil in
studies is stressed. Studies have shown that the seed extract has low levels of toxicity (Ali and
Blunden 2003; Effenberger and others 2010)
2.9. Potassium Chloride (KCl)
Western –style diets portray high salt and low potassium content, but the promotion of
low sodium diets is on the rise. It has been reported that reducing salt intake reduces the risk of
breast cancers (Strnad 2010). Potassium chloride (KCl) is the most widely used salt alternative
among other alternatives to sodium chloride (NaCl) salts (Naidu 2000; Samapundo and others
2010). Potassium is an essential dietary component. It is also one of the essential minerals
involved with cellular activities and heart stability in the body, at a normal range of 3.5-5.5
mmol/L (Zehender and others 1997). It is one of the three major electrolytes in the body that
maintains blood pH. It is absorbed through the small intestine and excess potassium is excreted
by the kidneys (Weatherby and Ferguson 2002).
One concern associated with potassium consumption is its toxicity level; however in
normal conditions, the kidney functions in maintaining a normal potassium level in the blood.
Thus, in a healthy population with normal kidney function, high potassium intake from foods
poses no risk as the kidney readily excretes excess potassium. In contrast, overuse of
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supplemental potassium can lead to toxicity in healthy individuals. The adequate intake of
potassium has been set at 4.7g/day by an Institute of Medicine committee. Potassium intake of
less than the adequate consumption amount is appropriate for individuals with impaired
potassium excretion due to effects from hyperkalemia (Caballero 2009). Hyperkalemia occurs
when elevated potassium levels surpass the amount the kidneys can excrete or when more than
18g of potassium is consumed orally at one time (Wilcox and Tisher 2009). An advantage of
potassium consumption is seen in the inverse relationship between dietary potassium and blood
pressure as an increase in daily consumption of potassium by 0.78g reduced blood pressure in
hypertensive patients (D'Elia and others 2011).
Another concern with the consumption of potassium chloride is its flavor. It has a salty
taste. However, when consumed in high amounts, KCl can impart bitterness and a metallic
aftertaste. Since KCl provides sodium reduction advantages, it is blended with other ingredients
to reduce its bitterness when used in formulations. Some KCl blends that have been used to
reduce or eliminate the bitter taste from KCl include yeast; monopotassium glutamate, potassium
citrate, potassium phosphate, L-glutamic acid, silicon dioxide, and KCl (Naidu 2000). Also,
methyl and ethyl maltol which are mouth-feel enhancing ingredients mask the bitter taste of KCl
in seasoned foods. Amino acids and organic acids are also said to reduce the bitterness of KCl
when precipitated from aqueous solution (Roy 1997).
The anti-cancer activity of KCl is linked with the apoptotic activity of heat shock proteins
(such as Hsp90) in the disease. Hsp90 is a chaperone protein which functions as a regulator of
the HER family. Hsp90 is over-expressed in human tumor cells by up to ten fold due to ATPase
activity. ATPase activity with Hsp90 has been proven to be reduced by KCl at 0.4% both in vivo
and in vitro (Kamal and others 2003; Rosen and others 2010).
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With the recent trend in using KCl as a substitute to NaCl in promoting low sodium diet,
not many studies have been done showing the effects of KCl on cancer cells. To the best of our
knowledge, no study has been done to see the effect of black seed oil combined with KCl on
breast cancer cells. It is expected that the combination of KCl with black seed oil will enhance
the inhibition activity of these dietary compounds against the highly aggressive TNBC.
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CHAPTER 3:
MATERIALS AND METHODS
3.1. Cell Lines and Reagents
Breast cancer cell line MDA-MB-231 was obtained from American Type Culture
Collection (ATCC, Manassas, VA). The cell line was propagated in Dulbecco’s Modified
Eagle’s Medium (DMEM) high glucose containing sodium bicarbonate, 15 mM HEPES, fetal
bovine serum to a final concentration of 10%, and nonessential amino acids. Cell propagation
media were from Invitrogen (Carlsbad, CA). Protease inhibitor cocktail was purchased from
Sigma Co (St. Louis, MO). Cold pressed extracted black seed oil was purchased from Botanic
Oil Innovations (Spooner, WI). Electrophoresis gels and reagents, and PVDF membranes were
from Invitrogen (Carlsbad, CA). Potassium chloride was purchased from EMD Chemical
(Gibbstown, NJ). Primary antibodies (ALDH1, CD44, ESA, p-ERK, p53, NF-κB, Bax, and Bcl2) and all secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Primary antibody (p21) was from Fisher Scientific (Fremont, CA). COX-2 was from
Cayman Chemical Company (Ann Arbor, MI). Primary antibody p-Akt was from Cell Signaling
Technology (Danvers, MA). Hsp90α was from Abcam (Cambridge, MA). All other reagents
were of analytical grade.
3.2. Gas Chromatography Analysis on Black Seed Oil
The gas chromatography profile for black seed oil in this study was obtained by analysis
on a Leco TOF GC/MS system equipped with an Agilent 6890 GC. A DB-5 (J &W Scientific,
Albany, NY) 30 m by 0.25 mm I.D. with a 0.25 μm film thickness was used with a flow rate of
1.0 mL/min. One microliter injections were made in splitless mode at an injection temperature
of 300 °C. The GC oven was initially held at 50 ºC for one minute then increased at 3 ºC/min to
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80 °C and then at a rate of 10 °C/min to 340 °C. The mass spectrometer was operated in electron
impact mode at 70 eV. Data was collected from m/z 35 to m/z 1000 and stored at 20
spectra/sec.
3.3. Cell Viability and Proliferation Assay
MDA-MB-231 cells (1 x 104 cells/well in 100 μL) were seeded in 96-well plates to
adhere overnight. BSO, KCl, or BSO with KCl were prepared as stock solutions (BSO was
prepared in DMSO and diluted in the cell culture media to achieve a final DMSO concentration
of less than 0.1% in each well or plate used in this study). The BSO treatment ranged from 00.22% BSO per media solution. KCl treatments ranged from 0-0.2% KCl, the KCl was directly
dissolved in cell culture media and pipetted on to cells in 96-well plates before incubation. The
combination treatments were done with 0.22% BSO and concentrations of KCl from 0-0.2%
KCl. The 96-well plates were incubated in the presence or absence of treatments followed by
stimulation with 100 ng/mL of IGF-I and additional incubation for 24 h, 48 h or 72 h in serumfree medium at 37 °C, 5% CO2 in a humidified incubator. After incubation, cell viability was
determined by MTS assay. CellTiter 96 AQueous One solution (Promega, Madison, WI) was used
following the MTS Assay protocol from Promega. 20μl of the MTS solution was added to each
well before incubation in a humidified 5% CO2 incubator at 370C for a minimum of one hour.
The absorbance was read at 490 nm using a Bio-Rad Model 680 micro plate reader (Hercules,
CA). The percentage of surviving cells were determined by reduction of MTS [(3-(4, 5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-trazolium, innersalt)].
Cell viability was normalized to the levels in untreated control cells to determine the percentage
of viable cells. Each experiment was performed in triplicate.
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3.4. Cell Cycle Analysis by Flow Cytometry
The technique of clinical flow cytometric DNA was done using the florescence activated
cell sorter (FACS), a flow cytometer that rapidly measures the fluorescence intensity based on
DNA content of a cell population that has been stained with a fluorescent DNA dye (Morgan
2007). Cells were seeded at a density of 2.5 x 106 cells in T-25 flasks overnight, and treated with
0.22% BSO (using DMSO as a vehicle), or KCl at 0.2 % , or the combination of 0.22% BSO
and 0.2% KCl for 72 h. To analyze the cell cycle after treatment period, cells were harvested by
trypsinization, washed with PBS, and stained using the Beckman-Coulter DNA Prep Reagents
Kit (cat # 6607055) following the manufacturers recommended staining procedure. Aliquot of
cells were first incubated and vigorously vortexed for 30 s with reagent 1 (RNase and detergent)
and stained for 1 h in the dark with reagent 2 (propidium iodide). The stained cells were read on
a Beckman-Coulter Epics FC500 flow cytometer using CXP software for the initial acquisition.
The data were then modeled using ModFit LT v3.2 software from Verity Software House
(Topsham, ME).
3.5. In vitro Angiogenesis
The Angiogenesis Assay kit was obtained from Chemicon (Temecula, CA). Human
umbilical vein endothelial cells (HUVEC) were used for this assay. The gel matrix was prepared
following the manufacturer’s instructions and then incubated at 37˚C to allow the matrix solution
to solidify. HUVEC at 1 x 104 cells per well were seeded onto the surface of polymerized
ECmatrix (Chemicon, Temecula, CA) alone, or treated with 0.22% BSO, or 0.2% KCl, or the
combination treatment (0.22% BSO/0.2% KCl). The plate was then incubated at 37˚C for 6h.
Tube formation was then inspected under an inverted light microscope (Olympus IX50) and
photographed.
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3.6. Total Cell, Cytoplasmic, and Nuclear Extracts Preparation and Protein Determination
Treated cells were grown as monolayer on T-75 flasks. Total cell extracts were prepared
as follows. Briefly, cells (1 x 107 cells) were treated with DMSO as vehicle, BSO, or KCl, or the
combination of BSO and KCl, washed with PBS, collected by scraping with RIPA buffer (50
mmol/L Tris-HCl, 150 mmol/L K NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
SDS, PMSF, orthovanadate, protease inhibitor mixture (added at a 1:100 dilution)) and incubated
at 4 °C for 30 min. Lysates were centrifuged at 14,000 x g for 10 min and the supernatant
recovered in other Eppendorf test tubes. Aliquots of supernatants were stored at -80 ºC for
Western blot.
Cytoplasmic and nuclear extracts were prepared as follows. Briefly, cells were washed
once with PBS and collected by scraping in 500 μL of hypotonic buffer (10 mmol/L HEPES pH
7.9, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.2 mmol/L PMSF, 0.5 mmol/L DTT, 5 mmol/L NaF, 1
mmol/L Na3VO4). Swollen cells were vortexed to shear cytoplasmic membranes. The mixture
was centrifuged at 14,000 x g for 30 seconds and the supernatant was retained as cytoplasmic
extracts. The nuclear pellet was resuspended in 50 μL of high-salt buffer (20 mmol/L HEPES pH
7.9, 25% glycerol, 1.5 mmol/L MgCl2, 1.2 mol/L KCL, 0.1 mmol/L EDTA, 420 mmol/L NaCl,
0.5 mmol/L DTT, and 0.2 mmol/L PMSF) by pipetting up and down, vortexed 10 s at high
setting, incubated for 30 min on ice, vortexed for 30 s at high setting, and centrifuged for 10 min
at 14,000 x g in a micro-centrifuge pre-cooled at 4ºC. The supernatant (nuclear fraction) was
transferred into other Eppendorf test tubes. Aliquots were kept at -80 ºC until use. Total protein
in total cell extracts, cytoplasmic, or nuclear fractions was determined by the DC Protein assay
(Bio-Rad, Hercules, CA).
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3.7. Western Immunoblot
Equal amounts (50 µg) of cytoplasmic or nuclear fractions from treated cells were diluted
with LDS sample buffer (Invitrogen, Carlsbad, CA), boiled, and loaded onto 4-12% Bis-Tris
gels. Proteins were separated and transferred to PVDF membranes. Membranes were blocked
with 5% BSA in TBS/Tween 20 (0.05%) following instructions from the antibody supplier,
followed by an overnight incubation with a primary antibody in 5% BSA in TBS/Tween20
following the manufacturer’s suggestion. Primary antibodies for stem cell surface markers
including ALDH1, ESA, and CD44 were analyzed. Primary antibodies associated with cell
proliferation including p-Akt, p-ERK, NFκB and COX-2 were also analyzed and furthermore,
we analyzed Hsp90α and some of its co-chaperone proteins including p53, p21, Bax, and bcl-2.
Visualization of the bound primary antibody was done by probing with alkaline phosphataseconjugated secondary antibodies following the manufacturer’s suggestion and exposure to
chromogenic detection reagent BCIP.
3.8. Statistical Analysis
Statistical analysis was conducted using the Statistical Package for the Social Sciences
(SPSS) software (version 15.0, 2006, SPSS Inc., Chicago, IL). Analysis of variance (ANOVA)
was conducted to examine the differences between treatments followed by post-hoc analysis
(LSD). A P-value of < 0.05 was considered to be statistically significant.

28

CHAPTER 4:
RESULTS AND DISCUSSION
4.1. Gas Chromatography-Mass Spectroscopy (GC-MS) Profile of Black Seed Oil
To determine the chemical profile of BSO, gas chromatography-mass spectrometric
analysis was performed on the oil. The results of GC-MS analysis of BSO indicated the presence
of thymoquinone, p-cymene, carvacrol, terpinolene, longifolene, hexadecanoic (palmitic) acid,
and linoleic (octadecanoic acid) as major compounds in the oil (Table 4.1). Black seed oil is a
vegetable oil rich in bioactive compounds. The strong neutraceutical potential of black seed has
been ascribed to its rich phytochemistry (Tauseef Sultan and others 2009).
Thymoquinone has been identified as the major bioactive component of black seed oil
among other compounds that have been identified in the oil (Effenberger and others 2010; GaliMuhtasib and others 2006; Velho-Pereira and others 2011). The concentration of TQ in the oil
used for this study was 25.2 g/kg of oil. Thymoquinone has been demonstrated both in vivo and
in vitro to possess anti-inflammatory and anti-oxidant characteristics, and to inhibit the
proliferation of various human cancers (Gali-Muhtasib and others 2006; Salem 2005; VelhoPereira and others 2011). For the study of the interactions of BSO and TNBC cells in vitro,
0.22% BSO containing 60 μM TQ was selected.
Thymoquinone works synergistically with other compounds in the oil such as carvacrol
(which is a phenol), and terpenes (such as p-cymene, terpineol). Terpenes have been found to
improve absorption and therefore aid absorption of black seed oil by the body (Harrewijn and
others 2001). Carvacrol is a phenolic compound which serves as an excellent natural antioxidant
in spices (Peter 2004). The bioactive compounds such as terpenes and phenols in black seed oil

29

are responsible for the pharmacological properties associated with the oil (Bhattacharjee and
Sengupta 2009).
Table 4.1: GC-MS Profile of Black Seed Oil
Peak No.

RT

Area %

Library/ ID

Ref #

CAS#

1

6.47

3.87

5- Isopropyl-2-methyl-1,3-cyclohxadiene

32141

000099-83-2

2

9.38

16.60

p-cymene

31918

025155-15-1

3

11.98

2.14

Terpinolene

31925

000586-62-9

4

12.25

0.90

Decamethylcyclopentasiloxane

313067

000541-02-6

5

14.33

23.11

Thymoquinone

64415

000490-91-5

6

14.87

1.43

Morphinan-6-ol

290923

006703-27-1

7

14.97

0.73

Carvacrol

46681

000499-75-2

8

16.30

1.43

Longifolene

121403

000475-20-7

9

16.62

1.53

093772-22-6

10

18.02

1.11

11

19.00

0.68

1-Methyl-3-(3,4-dimethoxyphenyl)-6,7291787
dimethoxyisochromene
3-(4-chlorophenyl)-4,6-dimethoxy-1-(prop- 302379
2’-enyl)indole-7-carbaldehyde
6-octenal, 3,7-dimethyl
52561

12

19.18

0.63

322218

003555-47-3

13

20.21

0.46

Trisiloxane, 1,1,1,5,5,5-hexamethyl-3,3bis[(trimethylsilyl)oxy]
Octamethyl-cyclotetrasiloxane

244218

000556-67-2

14

20.59

0.64

n-Hexadecanoic acid

195432

000057-10-3

15

20.7

1.15

13-isopimaradiene

216672

001686-56-2

16

21.45

3.76

Endo-2,2,3-trimethylbicyclo[2.2.1]heptane

34362

020536-40-7

17

21.78

20.72

Linoleic acid

226097

000060-33-3

18

21.96

8.98

1H-Purin-6-amine[(2-flourophenyl)methyl] 177443

074421-44-6

19

24.82

10.11

2-chloro-4-(2’-furanyl)-6-(2’thienyl)pyrimidine

000000-00-0
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202067

000000-00-0
000106-23-0

The oil consists of several fatty acids of which over 80% are unsaturated fatty acids. The
main fatty acids are linoleic acid, oleic acid, margaric acid, cis-11,14-eicosadeinoic acid, and
stearic acid (Amin and others 2010; MM and others 2011). The saturated free fatty acids in black
seed oil have been shown to induce apoptosis (Mu and others 2001). The absence of triglycerides
as observed in the GC-MS profile of this oil (Table 4.1) is an essential aspect of the nutritional
value of the oil. Breast cancer occurs less often in Asian countries such as India and China where
black seed oil is included in diet that in western countries such as the United States where black
seed oil is not popularly consumed (Lyn 2011).

4.2. Black Seed Oil or KCl or BSO with KCl Inhibits TNBC Cell Viability
To determine the efficacy of BSO or KCl or BSO with KCl against TNBC cells, MDAMB-231 viability was screened in the presence of 0-0.22% of BSO or KCl at 0-0.2% or their
combinations. MDA-MB-231 breast cancer cell line was used for this study. It was isolated from
pleural effusion of a breast cancer patient. This cell line is well defined in its growth with
invasive and metastatic characteristics. MDA-MB-231 cell line depicts triple negative
characteristics of being ER, PR, and HER-2 negative (Bachmeier and others 2007). The cells
have mesynchymal cell characteristics such as a strong ability to migrate (Yu and others 2009).
The measurement of cell viability is used to study integrated cellular changes. Cell
viability is simply the determination of the total number of live cells in a sample. This assay is
applied in the evaluation of treatment effectiveness against cancerous cells. Cell viability
determines the change in the total number of cells before and after treatment (Wu 2010).
The MTS solution used for this analysis reacts with the cells in media solution producing
a color change and the percentage of viable cells is relative to the color intensity of the cells in
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media solution when read with a micro plate reader. BSO treated cells were reduced to
approximately 20% at the highest concentration of treatment (0.22%) which contained 60µM TQ
(Figure 4.1). Preliminary studies done in the lab showed that TQ at 60µM significantly reduced
the percentage of viable cancer cells. In comparison to other concentrations of BSO used in this
study (0.07% and 0.15%), the highest concentration of 0.22% was more effective. Also, the
highest percentage reduction of viable MDA-MB-231 cells was observed after treatment for 72 h
in comparison to 24 and 48 h of treatment. Therefore, we used 0.22% and 72 h treatment for all
further analyses.

Cell Viability (% of control)

120
100
80

control

60

0.07% BSO
0.15% BSO

40

0.22% BSO
20
0
24h

48h

72h

Figure 4.1: Viability of Control and BSO treated MDA-MB-231 cells

Cell Viability (% of control)
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100
80

control

60

0.05% KCl
0.1% KCl

40

0.2% KCl
20
0
24h

48h

72h

Figure 4.2: Viability of Control and KCl treated MDA-MB-231 cells
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Figure 4.3: Viability of Control and BSO with KCl treated MDA-MB-231 cells

TNBC cells were also treated with 0.05, 0.1, and 0.2% KCl per media solution. The
percentage of viable TNBC cells reduced with increased treatment time and concentration of
KCl (Figure 4.2). After treatment with 0.2% KCl for 72 h, the percentage viable cells were
reduced to 19%. There were only slight differences between the different concentrations of KCl
in their percentage reduction of viable cells. The most effective treatment concentration and
time, 0.2% KCl and 72 h, were selected for further analyses.
For the combination treatments 0.22% BSO per media solution was combined with three
different concentrations of KCl (0.05, 0.1, and 0.2% KCl). A similar trend as with KCl
treatments was observed as in increased reduction in percentage viable cells with increased
treatment time and concentration of KCl (Figure 4.3).0.22% BSO combined with 0.2% KCl
reduced percentage viable cells to approximately 27%, while treatments with 0.1 and 0.05%
showed reduction to 34 and 37% viable cells respectively. BSO with 0.2% KCl which showed
highest reduction in percentage viable cells was selected for further analyses.
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4.3. Black Seed Oil or KCl or BSO with KCl Alters TNBC Cell Cycle Progression
To determine whether BSO or KCl or BSO with KCl induced reduction in TNBC cell
viability was associated with cell cycle perturbation, cell cycle analysis by flow cytometry was
performed and the distribution of cells in different phases of the cell cycle at 72 h of treatments
was measured. Cell cycle analysis can be used for cell activation and proliferation measurement.
Flow cytometry is used to determine cancer prognosis as abnormal DNA content would indicate
high risk for tumor recurrence and worse prognosis (Hedley and others 1987).
The TNBC cells were fixed with methanol and stained with propidium iodide (PI). The
PI intercalates into double stranded nucleic acids and can be excited by 488-nm lasers. The
enzyme RNAse is used for degradation of double stranded RNA so that only double stranded
DNA is left within the cell to bind to PI. When DNA binds to PI, florescence increases and PI
peaks can be emitted. Flow cytometry analysis gives the percentage of cells in the phases of cell
cycle (G0/G1, S, AND G2/M). Cell cycle analysis histograms report the G2 and M phases as
combined in view of the fact that they cannot be distinguished on DNA content basis.
After analysis of control and BSO or KCl or BSO with KCl treated TNBC cells, it was
observed that BSO treated MDA-MB-231 cells accumulated in the S-phase (from 6.24% in
control cells to 27.28% in BSO-treated cells) and increased cells in G2/M phase while there was
a decrease in G1 (Figure 4.5). The BSO with KCl combination treatment showed similar effect
in cell population as the BSO- treated cells. The combination treatment showed an accumulation
in the S phase with an increase from 6.24 in control to 17.4%, an increased population of cells in
the G2/M phase and a decrease in the G1 phase (Figure 4.7). KCl treated cells also accumulated
in the S phase with 21.58% and reduced in the G1 phase but showed a decrease in the G2/M
phase (Figure 4.6).
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Figure 4.4: Flow cytometry histogram for MDA-MB-231

Figure 4.5: Flow cytometry histogram for BSO treated MDA-MB-231
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Figure 4.6: Flow cytometry histogram for KCl treated MDA-MB-231

Figure 4.7: Flow cytometry histogram for BSO with KCl treated MDA-MB-231
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In conditions where there is adequate supply of nutrients, cell proliferation can occur.
This usually takes place by default in the G0 phase for most non-tumorigenic cells and this is
well controlled. However, genetic defects affect the cell cycle in cancer and lead to an
uncontrolled cell division which is a hallmark of cancer. In most cancer cells, the control of
progression in cell cycle is faulty, allowing cells with DNA errors (as with TNBC) to progress on
to the next phase of the cycle. The cancer cells disregard cell cycle control and remain in the
cycle causing more genetic diversity (Podo and others 2010). However based on the results
obtained with treated cells, there was increased number of cells in the S phase in comparison to
the control cells showing that BSO or KCl or BSO with KCl treatments interfere with the cell
cycle progression machinery at the reputed S phase restriction point or checkpoint.

4.4. Black Seed Oil or KCl or BSO with KCl Inhibits Endothelial Cell Tube Formation
To determine the effect of BSO or KCl or BSO with KCl on endothelial cell tube
formation, an in vitro angiogenesis tube formation assay was performed. Each of the steps in
angiogenesis, including basement membrane disruption, cell migration, cell proliferation, and
tube formation can be an intervention target and can be tested in vitro. Tube formation
angiogenesis assay is a very specific test used for angiogenesis (Auerbach and others 2003). On a
synthetic basement membrane matrix, cells are capable of morphological differentiation into an
extensive network of capillary-like structures composed of highly organized three-dimensional
cords. According to Bansode (2011), the alignment of endothelial cells in capillary-like
structures is a functional trait that is crucial to angiogenesis.
In this assay, the ability of endothelial cells to form three-dimensional tubular structures
was observed under a microscope. In the presence of 10ng/ml of VEGF, human umbilical vein
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endothelial cells (HUVEC) plated on the EC matrix aligned and formed capillary-like three
dimensional structures within 6h (Figure 4.8a). BSO or KCl or BSO with KCl inhibited tube
formation within 6h. Treatment with BSO or KCl or BSO with KCl completely disrupted the
capillary-like network of the ECmatrix (Figures 4.8b-d).

(a) Control HUVEC

(b)

(c) BSO treated cells

KCl treated cells

(d) BSO with KCl treated cells

Figure 4.8: Control and BSO-, KCl-, and BSO with KCl- treated HUVEC
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4.5. Black Seed Oil or KCl or BSO with KCl Down Regulates the Expression of Breast
Cancer Stem Cell Markers
To further determine the molecular mechanism associated with BSO- or KCl- or BSO
with KCl- mediated anti-proliferation activity on MDA-MB-231 cells, some relevant
overexpressed or activated signaling proteins in the TNBC cells were investigated. Protein
expression levels were determined by western blot analysis. Gene expression levels of breast
cancer stem cell markers were analyzed.
There have been no markers demonstrated to predict systemic metastasis development in
TNBC; however, there is increasing evidence that human breast cancers are driven by cancer
stem cells (CSC), which initiate tumors with self renewal properties (Charafe-Jauffret and others
2010). CSCs have been validated by different studies to be a small cell population resistant to
current anticancer therapies, antimitotic agents, and radiation. They are referred to as tumorinitiating cells which have been said to be probably responsible for the early recurrence in TNBC
due to their resistance to therapy. The ability of CSCs to sustain tumor formation and growth
gives rise to multi-lineage differentiated cells, which form the tumor (Hwang-Verslues and
others 2009; Lorico and Rappa 2011).
There are various breast cancer stem cell biomarkers, different breast cancer cell lines
and primary tumors show differences in expression of these CSC (Hwang-Verslues and others
2009). CD44, aldehyde dehydrogenase (ALDH1), and epithelial specific antigen (ESA) have
been recognized as triple negative breast CSC. CD44+/CD24- phenotype have shown high
capacity for tumor initiation and for expression of ESA which is known to be a cell surface
marker. ALDH is an enzyme involved in stem cell self-protection; tumors positive for ALDH
expression have been associated with a lack of expression of ER and PR, and a poor clinical
outcome (Croker and others 2009; Stratford and others 2010). BSO or KCl or BSO with KCl
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down regulated the expression of TNBC cell surface markers including ALDH1, CD44, and
ESA (Figure 4.9).

Ctrl

BSO

0.1%
KCl

0.2%
KCl

BSO/
0.2% KCl

ALDH1

CD44

ESA
Figure 4.9:

BSO or KCl or BSO with KCl treatments down regulate the expression of
TNBC stem cell markers

4.6. Black Seed Oil or KCl or BSO with KCl Affects the Activation of Signaling Pathways
Associated with Cell Proliferation and Metastasis
To determine the molecular mechanism associated with BSO or KCl or BSO with KCl
mediated anti-proliferation activity on TNBC cells, some relevant overexpressed or activated
apoptotic and cell survival signal transduction pathways associated with TNBC cells were
evaluated. Cell proliferation in TNBC is stimulated by the phosphatidylinositol-3 kinase
(PI3K)/Akt and/or the extracellular signal-regulated kinase (ERK) signaling pathways. BSO or
KCl or BSO with KCl inhibited PI3K pathway and suppressed the phosphorylation of Akt, or
ERK in MDA-MB-231 cancer cells (Figure 4.10). PI3K/Akt and NF-κB signaling pathways have
been shown to be signaling pathways associated with the growth, migration, invasion,
angiogenesis and metastasis in cancer progression (Rangaswami and others 2004; Wang and
others 2009). The PI3K/Akt pathway promotes cell proliferation and survival by modulating
several downstream signaling proteins including NF-κB. Results show that BSO or KCl or BSO
with KCl down-regulated the levels of NF-κB in TNBC cells (Figure 4.10). Cyclooxygenase
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(COX)-2 an inflammation marker associated with TNBC was also down-regulated by the
treatments used in this study. Anti-inflammatory properties of black seed oil have been
demonstrated in vivo and in vitro, and it was observed that the inflammation pathway
cyclooxygenase (COX) was inhibited (Salem 2005). It is conceivable that COX-2 downregulation was associated with the inhibition of NF-κB because the promoter sequence of COX-2
contains binding sites for NF-κB (Kaltschmidt 2002).

Ctrl

BSO

0.2%
KCl

BSO/
0.2% KCl

p-Akt

p-ERK

NF-κB

COX-2
Figure 4.10: BSO or KCl or BSO with KCl treatments down regulate cell proliferation and
progression markers
4.7. Black Seed Oil or KCl or BSO with KCl Affects the Activation of Signal Transduction
by Hsp90 and Client Proteins
To determine whether BSO or KCl or BSO with KCl inhibits Hsp90 activity, Western
blot analysis of Hsp90α was performed on MDA-MB-231 cells treated with BSO or KCl or BSO
with KCl. Hsp90 has been recognized as a master regulator of signal transduction (Boulon and
others 2008). Hsp90 is highly expressed in TNBC cells and assists in the conformational
maturation and stability of a range of “client proteins”. The overexpression of Hsp90 is mainly
due to ATPase activity as the chaperone activity of Hsp90 is dependent on the activity of this
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enzyme. Most Hsp90 client proteins are frequently mutated and include key mediator factors that
regulate cell proliferation, inhibit apoptosis, regulate cell cycle, enhance inflammation, and
sustain the survival of cancer cells. Inhibition or interruption of Hsp90 can destabilize these
client proteins and lead to cancer cell apoptosis. The clinical significance of Hsp90 is that many
of its client proteins are overexpressed in several types of cancer progression and proliferation
including TNBC (Bagatell and Whitesell 2004; Kang and others 2010). Inhibiting Hsp90
disrupts Hsp90 interactions with co-chaperones and leads to the degradation of client proteins
and weakening of processes fundamentally important to cancer cells including proliferation, cell
cycle regulation, and avoidance of apoptosis (Powers and Workman 2006; Zhang and others
2008; Zuehlke and Johnson 2010).

Ctrl

BSO

0.4%
KCl

BSO/
KCl

Hsp90

p53

p21

Bax

Bcl-2
Figure 4.11: BSO or KCl or BSO with KCl treatments inhibit activity of Hsp90 and other
apoptotic markers
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Western blot analysis indicated that the expression of Hsp90α was down-regulated in all
treated cells (Figure 4.11). The anti-cancer activity of KCl is linked with the apoptotic activity
of heat shock proteins in the disease. ATPase activity with Hsp90 has been proven to be reduced
by KCl at 0.2% both in vivo and in vitro (Kamal and others 2003).
The focus for this study was on Hsp90α, p53, NF-κB, bax, and bcl-2, because Hsp90
chaperones most of these proteins. Apoptosis induction is mediated by these proteins. Results in
Figure 4.11 indicate that the levels of mutated p53 in BSO- or KCl- or BSO with KCl -treated
TNBC cells were reduced compared to control cells. Thymoquinone from BSO is known to
induce apoptosis by p53 pathways in cancer cell lines (Gali-Muhtasib and others 2006). The
tumor suppressor protein p53 is a critical component of the apoptotic pathway as it controls the
expression of large numbers of genes. P53 is mutated and non functional in most tumors and has
been associated with poor prognosis of most cancers including TNBC. Due to a defective cell
cycle, frequent p53 mutations have been reported in TNBC cells (Oakman and others 2010; Podo
and others 2010). BSO or KCl or BSO with KCl decreased the levels of mutated p53 in MDAMB-231 cells. However it was shown that KCl alone and the BSO/KCl combination treatments
were more effective than BSO alone in down-regulating the expression of p53. A similar
observation was made with p21, as it was also down-regulated in treated MDA-MB-231 cells.
The Bcl-2 family which includes both proapoptotic proteins such as Bax and
antiapoptotic proteins such as Bcl-2 are associated with the regulation of cell growth and
apoptosis. Overexpression of Bcl-2 enhances cell survival by apoptosis suppression on the other
hand, Bax overexpression speeds up death (Wang and others 2009). Studies have shown that
thymoquinone from black seed oil inhibits anti-apoptotic Bcl-2 (Ait Mbarek and others 2007).
The levels of Bax proteins remained almost unchanged suggesting cell death by mixed apoptotic
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and non-apoptotic ways. Down-regulation of Bcl-2 expression suggested that cell death occurred
by apoptosis. The down-regulation of bcl-2 is likely linked to the ability of the treatments to
induce apoptosis in TNBC cells. It was observed that bcl-2 levels were down-regulated by all
treatments used (BSO or KCl or BSO/KCl). However unlike BSO and the BSO/KCl combination
treatment, KCl treated cells did not show up-regulation of Bax as should be the case for effective
induction of apoptosis. This shows an advantage of the combination treatment over the use of
KCl alone.
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CHAPTER 5:
SUMMARY AND CONCLUSION
The main objective of this study was to investigate the interaction of black seed oil
(BSO) or potassium chloride (KCl) or a combination of the oil with potassium chloride with the
biomarkers of triple negative breast cancer. To test this objective, the major bioactive compound
in black seed oil, thymoquinone, was identified in the commercially available oil used for the
study and cell viability, cell cycle, in vitro angiogenesis tube formation assays, as well as western
immunoblots on TNBC associated biomarkers were performed to examine treatment effects on
different aspects of TNBC. The expected results were that the treatments would inhibit the
proliferation and anti-apoptotic activity of TNBC cells.
The results prove that black seed oil or KCl or BSO with KCl treatments inhibited the
viability of MDA-MB-231 triple negative breast cancer cells after 72h exposure and led to downregulation of several factors associated with cell proliferation and apoptotic signal transduction
including Hsp90. Also the treatments disrupted tube formation in angiogenesis, and caused an
interruption in TNBC cell cycle progression. This shows that the treatments were effective in
targeting the hallmarks of breast cancer and characteristics of TNBC.
Overall, the analyses performed demonstrate that black seed oil and potassium chloride
have a strong potential and several advantages as preventive or therapeutic agents for this
aggressive deadly disease, triple negative breast cancer. However, further studies should be done
to examine the interaction of these anticancer agents in vivo.
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